News Release: EPS Corporation

July 23, 2013

Notice of the acquisition of Gleneagles CRC Pte Ltd shares (as a wholly-owned subsidiary)

We would like to announce that on July 23, 2013, we signed a purchase agreement to acquire (as a wholly-owned subsidiary) shares in Gleneagles CRC Pte Ltd (GCRC), headquartered in Singapore, from Parkway Holdings Limited and MITSUI & CO., LTD.

1. Reason for the acquisition of shares

With regards to our overseas CRO operation, in order to respond to the globalization of pharmaceutical companies, business activities have been carried out across the Asian region, in China, Hong Kong, Taiwan, Korea and Singapore, with Global Research Company, our in-house company, as the mainstay.

Meanwhile, GCRC is headquartered in Singapore, with bases in the Philippines, China, Australia, Thailand, Vietnam, Indonesia, South Korea, Malaysia and India. They support global pharmaceutical companies' clinical trials in the Asia-Pacific region. The parent company of GCRC is Parkway Holdings Limited which holds 51% of GCRC shares, and owns and operates hospitals and medical-related businesses in the Asian region through its subsidiary, while MITSUI & CO., LTD. holds 49%.

With the expansion of regional operations through this share acquisition as well as our mutually-complementary customer bases, we will further strengthen our framework in the Asia-Pacific region. This will expand our business and further advance our group's one-stop service in responding to the ongoing diversification and sophistication of our customers' needs.

In addition, in collaboration with MITSUI & CO., LTD. from whom we are to receive the share transfer, we have intended to consider plans including the business deployments that anticipate the needs of pharmaceutical companies in the Asia-Pacific region.

2. Overview of the transferred subsidiary (Gleneagles CRC Pte Ltd)

(1)	Name		Gleneagles CRC Pte Ltd (GCRC)				
(2)	Address		80 Robinson Road #02-00 Singapore 068898				
(3)	(3) Name & Title of Representative		Lim Cheok Peng, Chairman				
(4)			Contract Research Organization				
(5) Capital		SG\$7,191,827 (approx. JPY 569 million)					
(6)	Date Established		October 21, 1999				
(7)	Major Shareholders & Ownership Ratio		Parkway Holdings Limited 51% (510,000 shares), MITSUI & CO., LTD. 49% (490,000 shares)				
(8)	Relationship between this company and our company		Capital	N	No capital relationships that should be noted		
			Personnel	N	No personnel relationships that should be noted		
			Business	Т	Fransaction of services related to clinical trials		
(9)	9) Financial position and operating results of the past three years						
Fiscal Year Endi		Endi	ng December 2009		Ending December 2010	Ending December 2011	
Consolidated net assets ((762	(762,056) thousand yen		554,446 thousand yen	495,692 thousand yen	
Consolidated total assets		310,481 thousand yen		863,918 thousand yen	868,729 thousand yen		
Consolidated net sales		64	646,817 thousand yen		591,896 thousand yen	622,486 thousand yen	
Consolidated ordinary income			1,362 thousand yen		(6,727) thousand yen	(55,370) thousand yen	
Consolidated net income			580 thousand yen		(7,983) thousand yen	(56,715) thousand yen	

Note: At an exchange rate of SG\$1=JPY79.16.

Note: Financial position and business results for the fiscal year December 2012 are undisclosed because the audit is not completed.



3. Overview of the counterparties in the share acquisition

(1)	Name	Parkway Holdings Limited		
(2)	Address	111 Somerset Road, #15-01 Triple One Somerset, Singapore 238164		
(3)	Name & Title of	Ton Soo Long D		
	Representative	Tan See Leng, D	nector	
(4)	Business Activity	Shareholding		
(5)	Consolidated net assets	Undisclosed		
(6)	Consolidated total assets	Undisclosed		
(7)	Major Shareholders &	Dadaman Dantai Limita d 1000/		
	Ownership Ratio	Parkway Pantai Limited 100%		
		Capital	No capital relationships that should be noted	
	Relationship between	Personnel	No personnel relationships that should be noted	
(8)	this company and	Business	No business relationships that should be noted	
	our company	Status of	Not applicable	
		related parties		

Name	MITSUI & CO., LTD.	
Address	1-2-1 Otemachi, Chiyoda-ku, Tokyo, Japan	
Name & Title of Representative	Masami Iijima, President and Chief Executive Officer	
Business Activity	Utilizing the global operating locations, network and information resources, the company are multilaterally pursuing business that ranges from product sales, worldwide logistics and financing, through to the development of major international infrastructure and other projects in the following fields: Iron & Steel Products, Mineral & Metal Resources, Infrastructure Projects, Integrated Transportation Systems, Chemicals, Energy, Food Resources, Food Products & Services, Consumer Services, Innovation & Corporate Development Business.	
Consolidated net assets	3,440,104 million yen (as of March 31, 2013)	
Consolidated total assets	10,324,581 million yen (as of March 31, 2013)	
Major Shareholders & Ownership Ratio		Bank of Japan, Ltd. (Trust account) 8.22% rvices Bank, Ltd. (Trust account) 5.87%
Relationship between this company and our company	Capital Personnel Business Status of	No capital relationships that should be noted No personnel relationships that should be noted Transaction of services related to clinical trials Not applicable
	Name & Title of Representative Business Activity Consolidated net assets Consolidated total assets Major Shareholders & Ownership Ratio Relationship between this company and	Address Name & Title of Representative Utilizing the glob company are mult worldwide logist international infra Products, Minera Transportation Syservices, Consum Consolidated net assets Consolidated total assets Major Shareholders & Japan Trustee Se Capital Relationship between this company and 1-2-1 Otemachi, Masami Iijima, Products, Products, Minera Transportation Syservices, Consum Services, Consum Se

4. Number of shares acquired, acquisition cost, and status of shares held before and after acquisition

(1)	Number of shares held	- shares
(1)	before transfer	(Voting rights: 0%)
N C. da	1,000,000 shares	
(2)	Number of shares acquired	(Percentage of shares issued: 100%)
		Acquisition price: There is a non-disclosure agreement between the parties.
(2)	Number of shares held	1,000,000 shares
(3)	after transfer	(Voting rights: 100%)



5. Schedule

(1)	Resolution	July 23, 2013
(2)	Transfer of shares	July 30, 2013 (planned)

6. Future outlook

Although there are plans to position the company as a subsidiary in our consolidated financial statements, the impact on our consolidated profit in the near term remains minimal. In the future, if an impact on performance is foreseen, a timely notification will be issued when it is confirmed.